구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | belantamab mafodotin (Blenrep, GSK2857916, Unconjugated belantamab antibody and belantamab mafodotin) GlaxoSmithKline·Multiple Myeloma 1 trials |
|---|---|
Overview Program | Unconjugated belantamab antibody and belantamab mafodotin |
Overview Company | GlaxoSmithKline |
Overview Modality | ADC |
Overview Target | Multiple Myeloma |
Overview Indication | Multiple Myeloma |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Toxicology Major finding | Antibody-Drug Conjugates for Multiple Myeloma: Just the Beginning, or the Beginning of the End?. Multiple myeloma is a malignancy of immunoglobulin-secreting plasma cells that is now often treated in the newly diagnosed and relapsed and/or refractory settings with monoclonal antibodies targeting lineage-specific markers used either alone or in rationally designed combination regimens. Among these … |
Clinical Safety signal | Antibody-Drug Conjugates for Multiple Myeloma: Just the Beginning, or the Beginning of the End?. Multiple myeloma is a malignancy of immunoglobulin-secreting plasma cells that is now often treated in the newly diagnosed and relapsed and/or refractory settings with monoclonal antibodies targeting lineage-specific markers used either alone or in rationally designed combination regimens. Among these … |
Clinical Program phase | PHASE_2 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | belantamab mafodotin (Blenrep, GSK2857916, Unconjugated belantamab antibody and belantamab mafodotin) GlaxoSmithKline·Multiple Myeloma 1 trials |
|---|---|
Overview Program | Unconjugated belantamab antibody and belantamab mafodotin |
Overview Company | GlaxoSmithKline |
Overview Modality | ADC |
Overview Target | Multiple Myeloma |
Overview Indication | Multiple Myeloma |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Toxicology Major finding | Antibody-Drug Conjugates for Multiple Myeloma: Just the Beginning, or the Beginning of the End?. Multiple myeloma is a malignancy of immunoglobulin-secreting plasma cells that is now often treated in the newly diagnosed and relapsed and/or refractory settings with monoclonal antibodies targeting lineage-specific markers used either alone or in rationally designed combination regimens. Among these … |
Clinical Safety signal | Antibody-Drug Conjugates for Multiple Myeloma: Just the Beginning, or the Beginning of the End?. Multiple myeloma is a malignancy of immunoglobulin-secreting plasma cells that is now often treated in the newly diagnosed and relapsed and/or refractory settings with monoclonal antibodies targeting lineage-specific markers used either alone or in rationally designed combination regimens. Among these … |
Clinical Program phase | PHASE_2 |
추천 비교
추천 비교